CIK 0001701541
- Non-accelerated filer
- Smaller reporting company
Black Diamond Therapeutics, Inc.
Sign in to watch- Ticker
- BDTX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 814254660
- Phone
- +1 617-417-5868
- Business address
- 245 FIRST STREET, 18TH FLOOR, CAMBRIDGE, MA, 02142
- Former names
- Aset Therapeutics, Inc.
- 4 Grant or award Director acquired 3,843 shares (grant or award)
- 4 Grant or award Director acquired 6,170 shares (grant or award)
- 4 Grant or award Director acquired 5,526 shares (grant or award)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Grant or award Director acquired 7,646 shares (grant or award)
- 4 Grant or award Director acquired 6,848 shares (grant or award)
- 4 Open-market sale 10% owner sold 5,784,292 shares at an average $2.07 ($11,997,749)
- 4 Grant or award PRESIDENT & CEO acquired 75,000 shares (grant or award)
- 4 Grant or award CHIEF MEDICAL OFFICER acquired 75,000 shares (grant or award)
- 4 Grant or award CHIEF SCIENTIFIC OFFICER acquired 75,000 shares (grant or award)
- 4 Grant or award Jones Erika acquired 75,000 shares (grant or award)
- 4 Grant or award Hatzis-Schoch Brent acquired 75,000 shares (grant or award)
- 4 Grant or award Director acquired 5,750 shares (grant or award)
- 4 Grant or award Director acquired 5,150 shares (grant or award)
- 4 Grant or award Director acquired 4,500 shares (grant or award)
Page 2 of 15 · 283 filings